基于网络药理学探讨皂角刺治疗乳痈的作用机制

摘要 目的：基于网络药理学探讨皂角刺治疗乳痈的作用机制。方法：通过建立皂角刺药物靶点数据集、乳痈相关疾病靶点数据集，构建皂角刺治疗急性乳腺炎的蛋白互作（PPI）网络，构建并分析"皂角刺活性成分-潜在靶点-急性乳腺炎"网络。开展基因本体（GO）功能富集分析和京都基因与基因组百科全书（KEGG）通路富集分析，探讨皂角刺治疗乳痈的可能机制。结果：共得到皂角刺活性成分11个，筛选出活性成分所对应的不重复靶点共97个，其中1个活性成分无对应靶点。通过搜集GeneCards 和OMIM数据库，共得到292个急性乳腺炎的相关靶点基因。将疾病靶点基因与药物活性成分所对应的靶点进行比对后，得到10个交集靶点，即皂角刺治疗急性乳腺炎的潜在靶点。皂角刺活性成分按degree值排前3名的依次为槲皮素（quercetin）、漆黄素（fisetin）、山奈酚（kaempferol），其中皂角刺治疗乳痈的靶点包括白细胞介素-6（IL-6）、表皮生长因子受体（EGFR）、酪氨酸激酶受体2（ERBB2）、细胞间黏附分子-1（ICAM1）、雌激素受体1（ESR1）等5个关键靶点，主要涉及乳腺癌疾病通路、TNF信号通路和雌激素信号通路等3条信号通路。结论：皂角刺治疗乳痈的作用机制可能与机体的炎症反应以及雌激素水平变化等密切相关。     

Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?

The success in biomedical sciences such as genomics and proteomics is not paralleled in the medical product development methods. The consequence of this is a lack of translation into improved drug safety and efficacy. Therefore the US Food and Drug Administration (FDA) introduced the Critical Path Initiative in 2004 to modernize drug development and safety pharmacology. Bone is that largest tissue by weight, and is continuously remodelled. Changes in bone turnover lead to complications such as osteoporosis and fracture, that is associated with an increased mortality. Recent findings have identified bone as a possible endocrine organ and the availability of valid biochemical bone markers suggests that assessing bone turnover should also play an important role in general safety pharmacology.     

迷迭香酸的研究进展

迷迭香酸(Rosemarinic acid)是一种含多酚羟基的酸。迷迭香酸具有抗氧化及清除自由基作用和抗炎、免疫调节、抗血栓生成、抗菌、抗病毒、抗肾小球细胞增殖、抗抑郁等生物活性,广泛应用于食品、化妆品、医药等方面。本文对其生物及化学合成、生物技术生产、药理研究进展进行了综述。     

Cardioprotective role of G-Protein Coupled Estrogen Receptor 1 (GPER1)

Abstract

G-Protein Coupled Estrogen Receptor 1 (GPER1), also known as G-Protein Coupled Receptor 30 (GPR30) and initially considered an orphan receptor, has become one of the most important pharmacological targets in cardiovascular research. Since the gene encoding this putative receptor was cloned nearly 20 years ago, researchers have addressed its role in various aspects of physiology, including cardioprotection. Although extensive research has been carried out to understand the role of GPER1 as a pharmacological target to treat cardiovascular diseases, there are few current reviews addressing the overall cardioprotective benefits of this receptor and the signaling intermediates involved. This review considers the origins of GPER1, its cell biology, its physiological and pharmacological roles as a therapeutic target in cardiovascular disease, and what future research on GPER1 might entail. More specifically, the review focuses on GPER1 regulation of Angiotensin Type I Receptor (AT1R) and the role of estrogen receptors, epidermal growth factor receptor (EGFR) and matrix metalloproteinases (MMPs) in bringing about the cardioprotective effects of GPER1. Areas where improved knowledge of GPER1 biology is still needed to better understand the receptor’s cardioprotective effects are also discussed.     

Allosteric regulation of pentameric ligand-gated ion channels: An emerging mechanistic perspective

Pentameric ligand-gated ion channels (pLGICs) play a central role in intercellular communications in the nervous system by converting the binding of a chemical messenger—a neurotransmitter—into an ion flux through the postsynaptic membrane. They are oligomeric assemblies that provide prototypical examples of allosterically regulated integral membrane proteins. Here, we present an overview of the most recent advances on the signal transduction mechanism based on the X-ray structures of both prokaryotic and invertebrate eukaryotic pLGICs and on atomistic Molecular Dynamics simulations. The present results suggest that ion gating involves a large structural reorganization of the molecule mediated by two distinct quaternary transitions, a global twisting and the blooming of the extracellular domain, which can be modulated by ligand binding at the topographically distinct orthosteric and allosteric sites. The emerging model of gating is consistent with a wealth of functional studies and will boost the development of novel pharmacological strategies.     

基于分子对接和系统药理学小青龙汤治疗哮喘的作用机制

为从分子层面阐述小青龙汤治疗哮喘的作用机制,探索小青龙汤的潜在靶标,本研究检索中药系统药理学数据库及分析平台(TCMSP)并根据口服生物利用度(oralbioavailability,OB)、药物相似性(drug-likeness,DL)筛选出小青龙汤的活性成分,利用Pharmmapper数据库筛选小青龙汤潜在作用靶点,挖掘CTD、Genecards数据库以筛选与哮喘相关的作用靶点,利用Cytoscape 3.6.1软件构建小青龙汤的蛋白互作网络图、化合物靶点图,并通过计算拓扑学参数找到小青龙汤中关键的作用靶点和化合物。对小青龙汤对哮喘的作用靶点进行GO分析和KEGG分析。利用iGEMDOCK软件进行分子对接,预测作用靶点和主要化合物的结合度。通过筛选得到小青龙汤活性成分、潜在作用靶点;GO分析得到43个生物学过程、11个细胞组成和9个分子功能;KEGG分析包括PI3K-Akt信号通路、HIF-1信号通路、Wnt信号通路等。初步验证和预测了小青龙汤对治疗哮喘的作用机制,并为进一步深入揭示其作用机制提供参考。     

基于网络药理学的谷糠结合态多酚抗乳腺癌机制研究

本研究旨在探讨谷糠结合态多酚(bound phenol of inner shell,BPIS)发挥抗乳腺癌细胞活性的作用机制。首先采用细胞计数法检测BPIS对乳腺癌细胞以及正常乳腺细胞活性的影响;然后综合运用SEA、SIB以及GeneCards等数据库获得BPIS和乳腺癌的相关靶点,并分析活性成分与作用靶点的互作网络以及通路。本研究筛选得到BPIS抗乳腺癌相关靶点39个,主要涉及糖脂代谢和细胞自噬等生物过程以及MAPK、PI3K/AKT、FoxO等多条信号通,表明BPIS抗乳腺癌是多成分、多靶点、多通路协同作用的过程,而与细胞死亡相关的细胞自噬很可能在BPIS抑制乳腺癌过程中发挥主要作用。     

基于网络药理学的杜仲-山茱萸配伍治疗糖尿病的作用机制

为探讨杜仲-山茱萸治疗糖尿病的作用机制。研究利用网络药理学的方法,首先通过中药系统药理学数据库筛选出杜仲和山茱萸的活性成分和相关靶点,再利用DisGeNET、DrugBank等数据库筛选出糖尿病的潜在靶点。以STRING数据库对活性靶点构建蛋白互作网络(PPI)分析,采用Cytoscape3.7.0软件绘制其“成分-靶点-通路”的相互作用网络,通过CludterProfiler对靶蛋白进行生物过程、细胞组分及分子功能分析;京都基因与基因组(KEGG)的代谢通路分析。实验结果筛选得到杜仲-山茱萸有效成分30个,其中槲皮素、山奈酚、β-谷甾醇等成分对PTGS2、DPP4、ADRB2、PPARG等相关靶点通过IL-17信号通路、钙信号通路、脂肪细胞脂解的调控等参与氮化合物代谢过程、血液循环、脂肪细胞分化和血压调节等过程。综上,杜仲-山茱萸配伍治疗糖尿病存在多成分和多重药理作用机制,为进一步研究其治疗糖尿病药理实验提供了参考,也为其他中药的相关研究提供借鉴和参考。